Sugi Predict

Sugi Predict / Compounds / SCHEMBL4239168

SCHEMBL4239168

SCHEMBL4239168

Cc1cncc(C)c1C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HCAR2 Q8TDS4 6/20 0.46
▸ ALDH1A1 P00352 4/20 0.43
▸ MAPK1 P28482 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ NOTUM Q6P988 2/20 0.43
▸ CYP3A4 P08684 2/20 0.41
▸ ACHE P22303 1/20 0.41
▸ KDM4E B2RXH2 4/20 0.41
▸ KMT2A Q03164 3/20 0.41
▸ CYP2C9 P11712 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38
▸ MEN1 O00255 2/20 0.38
▸ GABRP O00591 1/20 0.38
▸ GABRD O14764 1/20 0.38
▸ GABRA1 P14867 1/20 0.38
▸ GABRB1 P18505 1/20 0.38
▸ GABRG2 P18507 1/20 0.38
▸ GABRB3 P28472 1/20 0.38
▸ GABRA5 P31644 1/20 0.38
▸ GABRA3 P34903 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28378544 0.86 KDM4E (0.48) HCAR2ALDH1A1MAPK1SMN1; SMN2NOTUM
SCHEMBL18171007 0.84 KDM4E (0.43) HCAR2ALDH1A1MAPK1SMN1; SMN2NOTUM
SCHEMBL6125229 0.84 ALDH1A1 (0.46) HCAR2ALDH1A1MAPK1SMN1; SMN2NOTUM
SCHEMBL31368733 0.84 HCAR2 (0.39) HCAR2ALDH1A1MAPK1SMN1; SMN2NOTUM
SCHEMBL29187966 0.84 HCAR2 (0.44) HCAR2ALDH1A1MAPK1SMN1; SMN2NOTUM
SCHEMBL21826343 0.80 ASPH (0.39) HCAR2ALDH1A1MAPK1SMN1; SMN2NOTUM
SCHEMBL31125579 0.80 ASPH (0.39) HCAR2ALDH1A1MAPK1SMN1; SMN2NOTUM
SCHEMBL5725168 0.79 CSNK1A1 (0.38) HCAR2ALDH1A1MAPK1SMN1; SMN2CYP3A4
SCHEMBL20267247 0.77 SIRT3 (0.47) HCAR2KMT2AMEN1POLBRAF1
SCHEMBL28000068 0.75 ALDH1A1 (0.40) HCAR2ALDH1A1MAPK1SMN1; SMN2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240270742-A1 SUBSTITUTED AMINO ACIDS AS INTEGRIN INHIBITORS PLIANT THERAPEUTICS INC (US) 2024-08-15 — — US disclosed
US-11952376-B2 Substituted amino acids as integrin inhibitors PLIANT THERAPEUTICS, INC. (US) 2024-04-09 — — US disclosed
US-20230391760-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO, INC. 2023-12-07 — — US disclosed
CN-116547279-A Heterocyclic GLP-1 agonists 加舒布鲁姆生物公司 2023-08-04 — — CN disclosed
US-20220144829-A1 AMINO ACID COMPOUNDS AND METHODS OF USE PLIANT THERAPEUTICS, INC. 2022-05-12 — — US disclosed
US-11180494-B2 Substituted amino acids as integrin inhibitors PLIANT THERAPEUTICS, INC. (US) 2021-11-23 — — US disclosed
EP-3863711-A1 AMINO ACID COMPOUNDS AND METHODS OF USE Pliant Therapeutics, Inc. (US) 2021-08-18 — — EP disclosed
CN-113195053-A Amino acid compounds and methods of use 普利安特治疗公司 2021-07-30 — — CN disclosed
US-20200109141-A1 AMINO ACID COMPOUNDS AND METHODS OF USE PLIANT THERAPEUTICS, INC. 2020-04-09 — — US disclosed
US-20150274720-A1 Azaquinazoline Inhibitors Of Atypical Protein Kinase C WINDTREE THERAPEUTICS, INC. 2015-10-01 — — US disclosed
US-9045429-B2 Substituted phenoxypyridines BAYER INTELLECTUAL PROPERTY GMBH (DE) 2015-06-02 — — US disclosed
WO-2014139983-A1 [1,2,4]TRIAZOLO[4,3-A]QUINOXALINES AS DUAL PDE2/PDE10 INHIBITORS H. LUNDBECK A/S (DK) 2014-09-18 — — WO disclosed
US-20130252922-A1 SUBSTITUTED PHENOXYPYRIDINES BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-09-26 — — US disclosed
US-7491735-B2 Chemokine receptor binding compounds GENZYME CORPORATION (US) 2009-02-17 — — US disclosed
EP-1708703-A4 CHEMOKINE RECEPTOR BINDING COMPOUNDS ANORMED INC (CA) 2008-04-09 — — EP disclosed
EP-1708703-A2 CHEMOKINE RECEPTOR BINDING COMPOUNDS ANORMED INC. (CA) 2006-10-11 — — EP disclosed
US-20050277670-A1 Chemokine receptor binding compounds ANORMED INC. 2005-12-15 — — US disclosed
WO-2005059107-A2 CHEMOKINE RECEPTOR BINDING COMPOUNDS ANORMED INC. (CA) 2005-06-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220144829-A1 AMINO ACID COMPOUNDS AND METHODS OF USE ITGB6, ITGA1, ITGAL HCAR2 1985/4885ALDH1A1 1981/4885MAPK1 808/4885
US-20230391760-A1 HETEROCYCLIC GLP-1 AGONISTS GLP1R, GIPR, GCGR HCAR2 671/4885ALDH1A1 840/4885MAPK1 707/4885
US-20200109141-A1 AMINO ACID COMPOUNDS AND METHODS OF USE ITGB6, ITGA1, ITGAL HCAR2 1985/4885ALDH1A1 1981/4885MAPK1 808/4885
US-11952376-B2 Substituted amino acids as integrin inhibitors ITGB6, ITGA1, ITGB1 HCAR2 2933/4885ALDH1A1 2168/4885MAPK1 1100/4885
US-20150274720-A1 Azaquinazoline Inhibitors Of Atypical Protein Kinase C PRKCQ, PRKCA, PRKCZ HCAR2 4518/4885ALDH1A1 4393/4885MAPK1 189/4885
US-11180494-B2 Substituted amino acids as integrin inhibitors ITGB6, ITGA1, ITGB1 HCAR2 2933/4885ALDH1A1 2168/4885MAPK1 1100/4885
US-20240270742-A1 SUBSTITUTED AMINO ACIDS AS INTEGRIN INHIBITORS ITGB6, ITGA1, ITGB1 HCAR2 2933/4885ALDH1A1 2168/4885MAPK1 1100/4885
US-20050277670-A1 Chemokine receptor binding compounds CCR5, CXCR3, CCL5 HCAR2 91/4885ALDH1A1 3358/4885MAPK1 1005/4885
US-20130252922-A1 SUBSTITUTED PHENOXYPYRIDINES VEGFA, FLT1, QDPR HCAR2 253/4885ALDH1A1 602/4885MAPK1 1965/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.